Substituted fused heterocyclic c-glycosides

Abstract

This invention relates to substituted fused heterocyclic C-glycosides, compositions containing them, and methods of using them, for example, for the treatment or prophylaxis of diabetes and Syndrome X.

1 - 22 . (canceled) 
     
     
         23 . A method for treating diabetes or Syndrome X or associated symptoms or complications thereof in a mammal, said method comprising administering to a mammal in need of treatment an effective amount of a compound selected from the group consisting of: 3-(4-Ethylbenzyl)-5-(β-D-glucopyranosyl)-1H-indole; 5-(β-D-Glucopyranosyl)-3-(4-methoxybenzyl)-1H-indole; 5-(β-D-Glucopyranosyl)-3-[2-(4-methoxyphenyl)-ethyl]-1H-indole and 3-(4-Ethylbenzyl)-4-(β-D-glucopyranosyl)-1H-indole; or a pharmaceutically acceptable salt thereof 
     
     
         24 . The method of  claim 23 , wherein said diabetes is type II diabetes. 
     
     
         25 - 56 . (canceled) 
     
     
         57 . A method for treating diabetes or Syndrome X, or associated symptoms or complications thereof in a mammal, said method comprising administering to a mammal in need of treatment an effective amount of a compound selected from the group consisting of: 2-(4-Ethylbenzyl)-4-(β-D-glucopyranosyl)-1H-indole; 3-[2-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-5-(β-D-glucopyranosyl)-1H-indole; 5-(β-D-Glucopyranosyl)-3-(5-methyl-2-thienyl)-1H-indole; 3-(4-Ethylbenzyl)-4-(β-D-glucopyranosyl)-3H-benzimidazole; 3-(4-Ethylbenzyl)-4-(β-D-glucopyranosyl)-1,3-dihydro-benzoimidazol-2-one and 3-(4-Ethylbenzyl)-4-(β-D-glucopyranosyl)-3H-benzotriazole; or a pharmaceutically acceptable salt thereof. 
     
     
         58 . The method of  claim 57 , wherein said diabetes is type II diabetes. 
     
     
         59 . A method for treating diabetes or Syndrome X, or associated symptoms or complications thereof in a mammal, said method comprising administering to a mammal in need of treatment an effective amount of a compound selected from the group consisting of 3-(4-Ethylbenzyl)-5-(β-D-glucopyranosyl)-1H-indole; 2-(4-Ethylbenzyl)-4-(β-D-glucopyranosyl)-1H-indole; 5-(β-D-Glucopyranosyl)-3-(5-methyl-2-thienyl)-1H-indole; 3-(4-Ethylbenzyl)-4-(β-D-glucopyranosyl)-3H-benzimidazole and 3-(4-Ethylbenzyl)-4-(β-D-glucopyranosyl)-3H-benzotriazole; or a pharmaceutically acceptable salt thereof. 
     
     
         60 . The method of  claim 59 , wherein said diabetes is type II diabetes.